Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the reduction in signs and symptoms of joint disease.


Clinical Trial Description

Psoriatic arthritis is a multi-faceted disease that impacts the joints, soft tissues, and skin, all of which not only results in functional disability and impaired quality of life, but participants with this disease also have increased mortality. Guselkumab is a monoclonal antibody that binds to human interleukin 23 (IL-23) and inhibits IL-23 specific intracellular signaling and subsequent activation and cytokine production. Investigation of guselkumab in this Phase 3b PsA clinical study is supported by the favorable efficacy and safety results from Phase 2 study of guselkumab in PsA and Phase 2 and Phase 3 studies in psoriasis including the subset of participants with PsA. The primary hypothesis is that guselkumab 100 milligram (mg) at Weeks 0, 4, and every 8 weeks (q8w) thereafter is superior to placebo which will be assessed by the proportion of participants achieving an American College of Rheumatology (ACR 20) response at Week 24. The study includes 2 periods: A 24-week double-blind, placebo-controlled period for the primary analysis of the efficacy and safety of guselkumab, compared with placebo and a 32-week active-treatment and safety follow-up period for additional analysis of the efficacy and safety of guselkumab. Safety will be monitored throughout the study (Up to Week 56). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03796858
Study type Interventional
Source Janssen Pharmaceutica N.V., Belgium
Contact
Status Completed
Phase Phase 3
Start date March 22, 2019
Completion date November 11, 2020

See also
  Status Clinical Trial Phase
Completed NCT02181673 - A Study of Golimumab in Participants With Active Psoriatic Arthritis Phase 3
Recruiting NCT04936308 - Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent Phase 3
Terminated NCT00090129 - Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 3
Withdrawn NCT03625089 - Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis N/A
Recruiting NCT05571696 - Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases N/A
Active, not recruiting NCT05071664 - A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis Phase 2
Completed NCT00938015 - Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis N/A
Suspended NCT03703934 - Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls
Recruiting NCT05092269 - A Long-term Extension Study of Ustekinumab in Pediatric Participants Phase 3
Terminated NCT05083078 - A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis Phase 1
Completed NCT02436785 - Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? N/A
Completed NCT02294227 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis Phase 3
Completed NCT00998829 - Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT00367237 - Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) Phase 3
Completed NCT00051623 - A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis Phase 3
Withdrawn NCT04680676 - A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis Phase 2
Completed NCT03008590 - Low Dose Naltrexone for Chronic Pain From Arthritis Phase 2
Recruiting NCT05657847 - Novel Complex Radiodiagnostics of Peripherial Arthropathies
Completed NCT02875184 - A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands